Home > Research > Publications & Outputs > Construction status and prospects of the Hyper-...

Links

Text available via DOI:

View graph of relations

Construction status and prospects of the Hyper-Kamiokande project

Research output: Contribution to Journal/MagazineConference articlepeer-review

Published
  • Hyper-Kamiokande Collaboration
Close
Article number1192
<mark>Journal publication date</mark>18/03/2022
<mark>Journal</mark>Proceedings of Science
Volume395
Publication StatusPublished
Early online date1/08/21
<mark>Original language</mark>English
Event37th International Cosmic Ray Conference, ICRC 2021 - Virtual, Berlin, Germany
Duration: 12/07/202123/07/2021

Conference

Conference37th International Cosmic Ray Conference, ICRC 2021
Country/TerritoryGermany
CityVirtual, Berlin
Period12/07/2123/07/21

Abstract

The Hyper-Kamiokande project is a 258-kton Water Cherenkov together with a 1.3-MW high-intensity neutrino beam from the Japan Proton Accelerator Research Complex (J-PARC). The inner detector with 186-kton fiducial volume is viewed by 20-inch photomultiplier tubes (PMTs) and multi-PMT modules, and thereby provides state-of-the-art of Cherenkov ring reconstruction with thresholds in the range of few MeVs. The project is expected to lead to precision neutrino oscillation studies, especially neutrino CP violation, nucleon decay searches, and low energy neutrino astronomy. In 2020, the project was officially approved and construction of the far detector was started at Kamioka. In 2021, the excavation of the access tunnel and initial mass production of the newly developed 20-inch PMTs was also started. In this paper, we present a basic overview of the project and the latest updates on the construction status of the project, which is expected to commence operation in 2027.

Bibliographic note

Funding Information: The REWIND trial was sponsored and funded by Eli Lilly and Company and led by an international steering committee that was coordinated by the Population Health Research Institute (Hamilton, ON, Canada), which also analysed the data for this report after the database was locked. ICON Clinical Research managed study sites and obtained data. Scientists employed by the funder were on the REWIND steering committee and contributed to trial design, trial implementation, and data interpretation. All authors and the sponsor jointly made the decision to submit for publication. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication. Publisher Copyright: © Copyright owned by the author(s).